Motus GI (NASDAQ:MOTS – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Motus GI (NASDAQ:MOTS – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($1.80) EPS for the quarter, beating analysts’ consensus estimates of ($2.20) by $0.40. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.07 million. Motus GI had a negative net margin of 5,331.94% and a negative return on equity of 152.78%. On average, analysts expect Motus GI to post $-9 EPS for the current fiscal year and $-7 EPS for the next fiscal year.
Motus GI Stock Performance
MOTS stock opened at $4.80 on Thursday. Motus GI has a 1-year low of $3.85 and a 1-year high of $18.40. The business’s 50-day moving average price is $5.21 and its two-hundred day moving average price is $6.22. The firm has a market cap of $13.21 million, a PE ratio of -0.62 and a beta of 1.96. The company has a current ratio of 6.63, a quick ratio of 6.42 and a debt-to-equity ratio of 1.20.
Wall Street Analysts Forecast Growth
Institutional Trading of Motus GI
An institutional investor recently bought a new position in Motus GI stock. Renaissance Technologies LLC bought a new stake in Motus GI Holdings, Inc. (NASDAQ:MOTS – Get Rating) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 73,500 shares of the company’s stock, valued at approximately $26,000. Renaissance Technologies LLC owned about 0.13% of Motus GI as of its most recent filing with the SEC. Institutional investors own 7.48% of the company’s stock.
Motus GI Company Profile
Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Recommended Stories
- Get a free copy of the StockNews.com research report on Motus GI (MOTS)
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
- AutoNation Stock is Firing on All Pistons
- Caterpillar Falls To Strong Support Near Bottom Of Range
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.